JapanStake
Pharmaceutical · Fiscal year end Dec 31

FunPep Company Limited

4881

株式会社ファンペップ

FIGI BBG00QX1Q1V84881.T4881 JPCorp. no. 1011001097115

Latest half-year results

First half · fiscal year to 2026-12 · filed 2026-08-14

For the first half of the fiscal year to 2026-12: Revenue ¥0 billion (+3465.4% YoY), Ordinary income ¥-0.5 billion, Net income ¥-0.6 billion.

This periodYear on year
Revenue¥2m+3465.4%
Ordinary profit−¥536m—
Net profit to owners−¥567m—

From the securities report on EDINET, which states no forecast. History via /v1/companies/4881/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2025-12-31
Revenue
¥0m
Net income
−¥1.9bn
ROE
—
Equity ratio
72.7%
Dividend / share
—
Employees
15
Revenue · ¥m
FY2022: ¥1m 1.07 FY2022FY2023: ¥1m 0.53 FY2023FY2024: ¥6m 6.13 FY2024FY2025: ¥0m 0.31 FY2025
Net income · ¥bn
FY2022: −¥1.2bn -1.17 FY2022FY2023: −¥0.9bn -0.93 FY2023FY2024: −¥0.9bn -0.89 FY2024FY2025: −¥1.9bn -1.91 FY2025
Fiscal yearRevenueNet incomeTotal assetsNet assetsROEEPSOperating CF
2025-12-31¥0m−¥1,912m¥1,981m¥1,464m—¥-50.2−¥1,388m
2024-12-31¥6m−¥889m¥3,111m¥2,547m—¥-31.98−¥537m
2023-12-31¥1m−¥933m¥2,491m¥2,302m—¥-39.63−¥989m
2022-12-31¥1m−¥1,173m¥2,993m¥2,695m—¥-61.04−¥1,053m

Indicators

Computed by us from filings · fiscal year to 2025-12-31
MetricValuePercentile among listed companies
ROE, %——
Ordinary margin-5,202.45860
Equity ratio, %72.7479.4
Revenue growth-0.94880.1
Net income growth-1.156.4
Operating cash flow / assets-0.70050.4
Policy-uncertainty measure0.45 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.
Fiscal & tax 1
Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 8.8% held by other listed companies.

Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.

Via /v1/companies/4881/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them
Internal control, 2026-03-24: see filing 上記の評価の結果、当連結会計年度末日時点において、当社の財務報告に係る内部統制は有効であると判断しました。 Filing

Segments, votes and tender offers

Stated in EDINET filings
Latest voting result: 2026-03-26 · 定款一部変更の件 · passed. /v1/companies/4881/voting

Ownership changes

All companies →

Trades by 5% holders

From the 60-day trade tables in 5% reports
¥85¥100¥115 2025-05-282026-03-24 2026-03-24 · sold 330,000 @ ¥88 · グロース・キャピタル株式会社2026-03-16 · sold 125,700 @ ¥115 · グロース・キャピタル株式会社2026-03-13 · sold 104,300 @ ¥102 · グロース・キャピタル株式会社2026-03-09 · sold 352,900 @ ¥85 · ネクスト・グロース株式会社2025-05-28 · bought 11 @ ¥109 · 株式会社SBI証券2025-05-28 · sold 21 @ ¥107 · 株式会社SBI証券
Bought SoldHover a dot for the trade
HolderPeriodNet sharesNet % of sharesAvg. filed priceRange
グロース・キャピタル株式会社2026-03-09 – 2026-06-02+1,361,300+2.79pt¥96.67¥88–115
ネクスト・グロース株式会社2026-03-09 – 2026-03-09-352,900−0.87pt¥85¥85–85
株式会社SBI証券2021-10-15 – 2025-05-28+492,066+3.14pt¥163.91¥107–247
individual filer2025-04-08 – 2025-05-21-500,000−1.31pt——
individual filer2022-02-14 – 2025-04-04-890,000−3.79pt¥220¥220–220
individual filer2024-12-10 – 2024-12-10-50,000−0.15pt——
individual filer2024-05-14 – 2024-05-1400.00pt——
塩野義製薬株式会社2024-03-21 – 2024-03-21+1,587,300+6.10pt¥126¥126–126
individual filer2022-10-01 – 2022-10-28-220,000−1.03pt¥155¥155–155
individual filer2022-10-01 – 2022-10-0100.00pt——
individual filer2021-12-16 – 2022-09-29-690,000−3.62pt¥170.65¥160–184
individual filer2021-10-13 – 2021-12-03-330,000−1.89pt¥342¥342–342

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4881/trades.

5% filings

Large shareholding reports on 4881
FiledFilerStakeChangeStated purpose
2026-06-09Growth Capital Inc.4.66%−1.21ptpure investment
2026-06-05Growth Capital Inc.20.72%−1.35ptpure investment
2026-06-05Growth Capital Inc.5.87%−1.00ptpure investment
2026-06-05Growth Capital Inc.18.35%−2.37ptpure investment
2026-06-05Growth Capital Inc.18.29%−0.06ptpure investment
2026-06-05Growth Capital Inc.16.53%−1.76ptpure investment
2026-06-05Growth Capital Inc.15.26%−1.27ptpure investment
2026-06-05Growth Capital Inc.13.84%−1.42ptpure investment
2026-05-29Growth Capital Inc.6.87%−1.06ptpure investment
2026-05-25Growth Capital Inc.7.93%−1.06ptpure investment

Cross-shareholdings

From the annual report's status of shareholdings
Listed strategic holdings
— issues
Book value
—
Sold in the year
— — issues
Bought in the year
— — issues
Mutual, both reports
0
Held by listed cos.
4

Held by: Shionogi & Co.,Ltd. 4507, MEDIPAL HOLDINGS CORPORATION 7459, AnGes, Inc. 4563, Sumitomo Pharma Co., Ltd. 4506

Purposes, all holdings and mutual flags via /v1/companies/4881/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2025-12-31
ShareholderSharesRatio
塩野義製薬株式会社2,682,5006.61%
楽天証券株式会社1,428,9003.52%
SBI4&5投資事業有限責任組合1,190,4002.93%
individual holder1,125,0002.77%
株式会社SBI証券903,9982.23%
株式会社ReBeage800,0001.97%
New Life Science1号投資事業有限責任組合793,6001.96%
有限会社アドバンステクノロジー700,0001.73%
individual holder648,6001.60%
株式会社メディパルホールディングス595,2001.47%

Get this as JSON

GET /v1/companies/4881
GET /v1/companies/4881/financials
GET /v1/companies/4881/details
GET /v1/companies/4881/segments
GET /v1/companies/4881/voting
GET /v1/companies/4881/tender-offers
GET /v1/companies/4881/indicators
GET /v1/companies/4881/earnings-releases
GET /v1/events?ticker=4881
GET /v1/companies/4881/trades         
GET /v1/companies/4881/cross-holdings 
GET /v1/companies/4881/brief          

Plans from $9 a month · Documentation